Calamos Advisors’s NovoCure NVCR Stock Holding History

Calamos Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,954	Closed	-$272K	–	1180
2026 Q1	$272K	Buy	+24,954	New	+$312K	﹤0.01%	1062
2020 Q2	–	Sell	-18,882	Closed	-$1.27M	–	758
2020 Q1	$1.27M	Buy	+18,882	New	+$1.49M	0.01%	573

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Calamos Advisors's NVCR Position: Q2 2026 in Review

Calamos Advisors sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 24,954 shares — an estimated $272K sold.

Calamos Advisors first reported a position in NVCR in Q1 2020 and held it in 2 quarters. The position peaked at $1.27M in Q1 2020. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Calamos Advisors reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 24,954 NovoCure shares in Q2 2026, an estimated $272K.
Calamos Advisors first reported a position in NovoCure in Q1 2020 and held it in 2 quarters.
Calamos Advisors's NovoCure position peaked at $1.27M in Q1 2020.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.